On January 20, 2023, the Editorial Office of Cancer Drug Resistance (CDR) was honored to interview Editorial Board member Dr. Zhiqing Huang. She is an Assistant Professor in the Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Duke University Medical Center, Durham, NC, USA. In November 2022, Dr. Huang joined our editorial board based on her recognition of publications on ovarian cancer resistance in CDR. In order to further enhance the mutual understanding between the Editorial Office and Dr. Huang, we had an in-depth interview with her.
In the interview, Dr. Huang summarized the content of her paper "Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance" published in Molecular Cancer Therapeutics in 2021. She said that cancer drug resistance is essential, but research on it has been slow. Therefore, she will continue her research in the area. In addition, she pointed out that biomarkers are required for early detection to predict cancer chemical sensitivity, and chemo-resistance also deserves much more attention, both of which may contribute to prolonging survival.
In the next research, she and her team want to identify what are the contributing factors in the tumor microenvironment that support cancer. Furthermore, she stresses that age has been shown to correlate with cancer development.
Dr. Huang said she enjoys teaching at Duke University. She is pleased with students who want to pursue a career in medical research. Additionally, she is also keen to organize cancer-related seminars. She has been organizing the Monthly Seminar Series for the Division of Reproductive Sciences at the Department of Ob/Gyn, Duke University for scholars to share their ideas and information about cancer research.
Introduction of Dr. Zhiqing Huang
Dr. Zhiqing Huang is an Assistant Professor in the Department of Obstetrics and Gynecology, Division of Reproductive Sciences, at Duke University Medical Center and a member of the Duke Cancer Institute. Her research includes: the factors in the tumor microenvironment that contribute to ovarian cancer progression; new drug development for recurrent ovarian cancer treatment; the early DNA methylation profiles that contribute to cancer development in late life; the special changes in the tumor microenvironment; epigenetics and epigenomics.
Respectfully Submitted by the Journal Editorial Office
Cancer Drug Resistance